E-cigarette Use and Indicators of Cardiovascular Disease Risk
- 221 Downloads
Purpose of Review
The aim is to provide a detailed review of literature from studies examining the relation of electronic cigarette (e-cigarette) use to indicators of risk for cardiovascular disease. In addition to discussing clinical and cell culture studies, we discuss possible mechanisms for the observed effects.
Studies have compared the effect of e-cigarette use (or vapor) and combustible cigarette smoking on a range of measures. These include heart rate, blood pressure, and vagal tone; aortic stiffness and endothelial function; platelet aggregation and adhesion; expression of genes for antioxidant defense and immune system function; and indices of oxidative stress. The majority of studies found some evidence of a significant risk effect for e-cigarettes, although the evidence was not totally consistent within and between studies. Suggestive evidence also implicates a possible effect of e-cigarettes on inflammation processes. The magnitude of the effect for e-cigarettes was sometimes lower than those found for cigarettes, but several studies showed comparable effects.
The findings overall provide evidence of some risk to the cardiovascular system from e-cigarettes, but conclusions are qualified because each study was heterogeneous in its design and evidence on cardiac morbidity from prospective human studies is not yet available. The studies have helped to identify possible agents and mechanisms for producing risk, including reactive oxygen species and oxidative stress, fine and ultrafine particles, and nicotine. Longitudinal data from clinical and epidemiological studies are needed to clarify these relationships in healthy populations and investigate the impact of e-cigarette use among persons with pre-existing cardiovascular disease.
KeywordsE-cigarettes Cardiovascular disease Heart disease Vascular disease
Compliance with Ethical Standards
Conflict of Interest
Rebecca J. Schweitzer and J. Dusty Behner each declare no potential conflicts of interest.
Dr. Wills reports grants from National Cancer Institute during the conduct of the study.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.National Institute of Drug Abuse. Drug Facts: E-cigarettes. 2015.Google Scholar
- 2.• Farsalinos KE, Polosa R. Safety evaluation and risk assessment of e-cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014;5:67–87. doi: 10.1177/2042098614524430. Provides a review on the safety of using e-cigarettes for smoking cessation, a topic of importance for regulation and future research. CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Schoenborn CA, Gindi RM. E-cigarette use among adults: United States, 2014. NCHS data brief no. 217. US Department of Health and Human Services, CDC: Hyattsville; 2015.Google Scholar
- 5.Miech RA, Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975–2015: volume 1: secondary school students. Ann Arbor: Institute for Social Research, University of Michigan; 2016.Google Scholar
- 6.U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general Atlanta, GA: Centers for Disease Control and Prevention.2014.Google Scholar
- 15.McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. E-cigarettes for smoking cessation and reduction. Cochrane Database of Systematic Review 2014:(CD010216). Doi: 10.1002/14651858.CD010216.Google Scholar
- 16.Soneji S, Barrington-Trimis JL, Wills TA, Leventhal AM, Unger JB, Gibson LA, et al. E-cigarette use and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr. 2017; in pressGoogle Scholar
- 19.• Bhatnagar A. E-cigarettes and cardiovascular disease risk: evaluation of evidence, policy implications, and recommendations. Curr Cardiovasc Risk Rep. 2016;10:1–10. doi: 10.1007/s12170-016-0505-6. Importance for an overview of the effects of e-cigarette use on cardiovascualr disease and implications for use and policy. CrossRefGoogle Scholar
- 21.World Health Organization. WHO Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide. Geneva, Switzerland. 2005.Google Scholar
- 22.U.S. Department of Health and Human Services. E-cigarette use among youth and young adults: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2016.23.Google Scholar
- 27.Duprez D. Arterial stiffness and cardiovascular disease. E-Journal of Cardiology Practice 2002:1.Google Scholar
- 29.Farsalinos K, Cibella F, Caponnetto P, Campagna D, Morjaria JB, Battaglia E, et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to e-cigarettes. Intern Emerg Med. 2016;11:85–94. doi: 10.1007/s11739-015-1361-y.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Heiss C, Amabile N, Lee AC, Real WM, Schick SF, Lao D, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol. 2008;51:1760–71. doi: 10.1016/j.jacc.2008.01.040.CrossRefPubMedGoogle Scholar
- 34.• Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regul Toxicol Pharmacol. 2016;81:S1–s14. doi: 10.1016/j.yrtph.2016.10.003. Randomized trial showing the effects for smokers substituting e-cigarette use for smoking tobacco cigarettes. CrossRefPubMedGoogle Scholar
- 35.• Teasdale JE, Newby AC, Timpson NJ, Munafo MR, White SJ. Cigarette smoke but not e-cigarette aerosol activates a stress response in human coronary artery endothelial cells in culture. Drug Alcohol Depend. 2016;163:256–60. doi: 10.1016/j.drugalcdep.2016.04.020. Investigates the stress of heart cells from e-cigarette use. CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Hom S, Chen L, Wang T, Ghebrehiwet B, Yin W, Rubenstein DA. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of e-cigarette extracts of variable nicotine concentrations. Platelets. 2016;27:694–702. doi: 10.3109/09537104.2016.1158403.CrossRefPubMedGoogle Scholar
- 39.Lerner CA, Sundar IK, Yao H, Gerloff J, Ossip DJ, McIntosh S, et al. Vapors produced by e-cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One. 2015;10:e0116732. doi: 10.1371/journal.pone.0116732.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2016;311:L135–44. doi: 10.1152/ajplung.00170.2016.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.McNeill A, Brose LS, Calder R, Hitchman SC, Hajek P, McRobbie H. E-cigarettes: an evidence update: a report commissioned by Public Health England: Public Health England. 2015.Google Scholar
- 45.Australian Government: National Health and Medical Research Council. NHMRC CEO Statement: E-cigarettes (E-Cigarettes) 2017.Google Scholar
- 53.Benowitz NL, Fraiman JB. Cardiovascular effects of e-cigarettes. Nat Rev Cardiol. 2017. Epub ahead of print. Doi: 10.1038/nrcardio.2017.36.
- 54.Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010;122:1520–44. doi: 10.1161/CIR.0b013e3181f432c3.CrossRefPubMedGoogle Scholar